Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clomipramine is a tricyclic antidepressant (TCA) primarily indicated for the treatment of obsessive-compulsive disorder (OCD) in adults and children aged 10 years and older. It acts mainly as a potent serotonin reuptake inhibitor, increasing serotonin levels in the brain to help maintain mental balance. Clomipramine also inhibits norepinephrine reuptake through its active metabolite, desmethylclomipramine, and exhibits antagonistic activity at several serotonin receptor subtypes. Additional pharmacological effects include alpha-1 adrenergic receptor blockade and sodium channel inhibition, which may contribute to its analgesic properties in neuropathic pain. The drug is available as oral capsules in various strengths[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clomipramine.